{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000164","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2022-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.884618+00:00","generated_at":"2026-06-27T09:47:33.609768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva reports FY 2021 revenue down 5% to $15.9B; GAAP EPS $0.38; Q4 GAAP loss","bullets":["FY 2021 revenues $15.9B, down 5% YoY; GAAP diluted EPS $0.38 vs -$3.64 in 2020.","Q4 2021 GAAP diluted EPS $(0.14); Non-GAAP diluted EPS $0.77.","FY 2021 non-GAAP diluted EPS $2.58 (flat YoY); free cash flow $2.2B.","2022 outlook: revenue $15.6-$16.2B, non-GAAP EPS $2.40-$2.60, FCF $1.9-$2.2B."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000164","json":"https://secwatch.observer/filing/0001157523-22-000164.json","markdown":"https://secwatch.observer/filing/0001157523-22-000164.md","text":"https://secwatch.observer/filing/0001157523-22-000164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752322000164/0001157523-22-000164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752322000164/a52576299.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:47:33.609768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}